Risperdal

Johnson & Johnson’s Janssen Pharmaceuticals Receives Mixed Verdict in Second Risperdal Trial

On Friday, March 20, 2014, a jury in Philadelphia found that Johnson & Johnson’s Janssen Pharmaceuticals failed to warn consumers that the antipsychotic drug Risperdal could cause male breast growth, but it awarded no damages finding causation of a direct link between the drug and the plaintiff’s condition was not conclusively proved. The case was […]